Immune Regulation News 8.26 July 22, 2016 | |
| |
TOP STORYGo-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer Using advanced imaging technology that allowed them to spy on interactions among cells in the lymph nodes of living mice, scientists have identified a cell that is a key player in mounting the immune system’s defense against cancer. [Press release from University of California, San Francisco discussing online prepublication in Cancer Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The ER Membrane-Anchored Ubiquitin Ligase Hrd1 Is a Positive Regulator of T-Cell Immunity Scientists showed that genetic deletion of Hrd1 in mice inhibits T-cell proliferation, production of interleukin-2 (IL-2), and differentiation of helper T (Th)1 and Th17 cells, and consequently protects mice from experimental autoimmune encephalomyelitis. [Nat Commun] Full Article The ability of Netrin-1 to interact with lymphocytes and its in-depth effects on leukocyte migration are poorly understood. Researchers profiled the mRNA and protein expression of known Netrin-1 receptors on human CD4+ T cells. [J Immunol] Abstract Scientists showed that epidermal growth factor receptor (EGFR) signaling pathway play a role in regulation of Treg cells in cancer patients. [J Biol Chem] Abstract | Full Article Researchers combined adoptive cell transfer with ablation of the checkpoint protein Src homology 2-domain-containing phosphatase 1 (SHP-1). [Immunol Cell Biol] Full Article Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice Scientists used the chimeric FoxP3-Fc(IgG) fusion construct/protein to effectively stimulate the immune responses against regulatory T cells. [J Immunother] Abstract Multiple sclerosis is an autoimmune disease characterized by defect in regulatory function of CD4+CD25+ T cells. Investigators demonstrated difference in proportion of regulatory T cells CD4+CD25+FoxP3+CD127low within the same patients’ relapse and remission. [Autoimmunity] Abstract The growth inhibitory effects of bufadienolide compounds were investigated in two intractable cancer cells, a human glioblastoma cell line U-87 and a pancreatic cancer cell line SW1990. [Oncol Rep] Abstract PD-1+ and Foxp3+ T Cell Reduction Correlates with Survival of HCC Patients after Sorafenib Therapy Based on preclinical and human studies, researchers hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive network in hepatocellular carcinoma (HCC) patients. [JCI Insight] Full Article | Press Release Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News. | |
| |
REVIEWSHydrogen Sulfide Regulates Homeostasis of Mesenchymal Stem Cells and Regulatory T Cells The growing number of diverse targets for which hydrogen sulfide (H2S) serves as a gasotransmitter has been extensively reviewed elsewhere. The authors discuss current emerging evidence that H2S regulates mesenchymal stem cell and T-cell functions. [J Dent Res] Abstract Visit our reviews page to see a complete list of reviews in the immune regulation research field.
| |
INDUSTRY NEWSZIOPHARM Oncology, Inc. announced plans for a Phase I adoptive cellular therapy clinical trial utilizing autologous T cells transduced with lentivirus to express a CD33-specific chimeric antigen receptor (CAR) in patients with relapsed or refractory acute myeloid leukemia. [ZIOPHARM Oncology, Inc.] Press Release VAXIMM Initiates Phase I Translational Study in Glioblastoma with Oral T-Cell Immunotherapy, VXM01 VAXIMM AG announced the treatment and successful operation of the first patient in a Phase I clinical trial. [VAXIMM AG] Press Release Targazyme, Inc. announced that it has enrolled the first patient in a Phase I/II TZ 101-treated regulatory T cell clinical study. This Phase I/II clinical study will evaluate the efficacy and safety of TZ101-treated regulatory T cells in the prevention and treatment of acute and chronic graft-versus-host-disease in stem cell transplants. [Targazyme, Inc. (Marketwired)] Press Release Three Leaders in Lupus Merge to Form the Lupus Research Alliance The Alliance for Lupus Research, the Lupus Research Institute, and the S.L.E. Lupus Foundation announced the merger of the three organizations to form the Lupus Research Alliance. [The Alliance for Lupus Research] Press Release Hansa Medical Acquires Rights to Cancer Immunotherapy Using Antibody-Modulating Enzymes Hansa Medical AB announced the acquisition of UK based Immago Biosystems Ltd, a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using antibody-modulating enzymes. [Hansa Medical AB] Press Release | |
From our sponsor: Learn how to isolate cells from whole blood in 25 minutes. Watch the video.
| |
POLICY NEWSDrugs Watchdog Thwarting UK Progress in Stem Cell Therapy, Report Says Britain’s hopes of leading the world in revolutionary therapies that regenerate damaged body parts are under threat because the NHS drugs watchdog cannot properly evaluate them, a report says. [The Guardian] Editorial | Report Science’s Status Shifts in New Brexit Government Three weeks after UK voters chose to leave the European Union, the country has a new prime minister, Theresa May — and a revamped administration that is poised to change science’s place in government. [Nature News] Editorial Science Under Siege: How Venezuela’s Economic Crisis Is Affecting Researchers The political and economic crisis in Venezuela continues to worsen. As the price of oil — the country’s major export — has fallen, Venezuela has struggled to pay for imported goods while maintaining socialist economic policies put in place by former president Hugo Chávez. [Nature News] Editorial Younger Researchers Win NIH Grants at Rates Similar to Their Elders Younger biomedical researchers—those between 35 and 39—are about as likely to win funding from the National Institutes of Health (NIH) as their elders, according to a study published in Cell Stem Cell. This finding seems to upend the widespread impression that older scientists have higher success rates than their juniors in the competition for grants. [Science Careers] Editorial | Article Bill to Reform U.S. Skilled Worker Visa Programs Is Effort to ‘Build Momentum’ Lawmakers don’t usually acknowledge that the bills they introduce in Congress have little chance of passage in the near future, but that’s what Representative Bill Pascrell, Jr., (D-NJ) did in a phone press conference to discuss the H-1B and L-1 Visa Reform Act of 2016, which he introduced in the House of Representatives. Still, “we’re trying to build momentum” and raise awareness of the need to reform these high-skill guest worker visa programs, he said. [Science Careers] Editorial
| |
EVENTSNEW Cancer Vaccines 2016 Visit our events page to see a complete list of events in the immune regulation community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Immunology (Inserm) Technical Sales Representative (STEMCELL Technologies Inc.) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Scientist – Bioengineering (STEMCELL Technologies Inc.) Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.) Postdoctoral Fellow – Cancer Biology and Cancer Immunology (Fox Chase Cancer Center) Senior Faculty Leadership Position – Immunology (Fred Hutchinson Cancer Research Center) Postdoctoral Position – Immunology (Ludwig-Maximilians-Universität) Assistant or Associate Professor – Cancer Immunology (University of Virginia) Research Postdoctoral Fellow – Molecular Immunology/Cell Signaling (Baylor Scott & White Health) Postdoctoral Scientist – Novel Immune Modulating Drugs (Celentyx) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Immune Regulation News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Immune Regulation News Volume 8.26 | Jul 22 2016